早产儿产后皮质类固醇预防支气管肺发育不良:系统综述与网络Meta分析
该系统综述与网络Meta分析纳入62项随机临床试验共5559名胎龄≤32周的早产儿,评估14种产后皮质类固醇方案预防支气管肺发育不良(BPD)或死亡的效果。结果显示中等早期启动中等累积剂量地塞米松(MoMdDX)在降低BPD或死亡风险方面排名最优(SUCRA 0.91),但高血压风险升高;证据质量低。
要点
- MoMdDX可能为预防BPD或死亡的最适方案,但需警惕高血压风险。
- 多种方案可降低BPD或死亡风险,但各有特定安全风险。
- 早启动全身氢化可的松与胃肠穿孔风险升高相关。
核心结论
- MoMdDX可能是预防36周PMA时BPD或死亡的最适产后皮质类固醇方案,但存在高血压风险,证据质量低。
研究设计与样本
- 系统综述与网络Meta分析,检索PubMed、CENTRAL、Embase、ICTRP和CINAHL至2020年8月25日,纳入62项随机临床试验共5559名胎龄≤32周且生后4周内启动皮质类固醇的早产儿。
主要发现
- EHC与BPD或死亡风险降低相关(RR 0.82;95%CrI 0.68-0.97)。
- EIFLUT与BPD或死亡风险降低相关(RR 0.75;95%CrI 0.55-0.98)。
- LaHdDX与BPD或死亡风险降低相关(RR 0.70;95%CrI 0.54-0.87)。
- MoHdDX与BPD或死亡风险降低相关(RR 0.64;95%CrI 0.48-0.82)。
- ITBUD与BPD或死亡风险降低相关(RR 0.73;95%CrI 0.57-0.91)。
关键数值与推荐
- MoMdDX与BPD或死亡风险降低相关(RR 0.61;95%CrI 0.45-0.79),SUCRA 0.91排名第一。
- MoHdDX的SUCRA为0.86,LaHdDX的SUCRA为0.76。
- ITBUD与拔管成功相关(RR 4.36;95%CrI 1.04-12.90)。
- LaHdDX与拔管成功相关(RR 11.91;95%CrI 1.64-44.49)。
- EHC与胃肠穿孔风险升高相关(RR 2.77;95%CrI 1.09-9.32)。
临床怎么用
- 临床决策需权衡MoMdDX降低BPD或死亡获益与其高血压风险。
- 使用EHC时需警惕胃肠穿孔风险。
- 使用MoHdDX时需警惕肥厚型心肌病风险。
局限性
- 证据质量低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The safety of postnatal corticosteroids used for prevention of bronchopulmonary dysplasia (BPD) in preterm neonates is a controversial matter, and a risk-benefit balance needs to be struck. OBJECTIVE: To evaluate 14 corticosteroid regimens used to prevent BPD: moderately early-initiated, low cumulative dose of systemic dexamethasone (MoLdDX); moderately early-initiated, medium cumulative dose of systemic dexamethasone (MoMdDX); moderately early-initiated, high cumulative dose of systemic dexamethasone (MoHdDX); late-initiated, low cumulative dose of systemic dexamethasone (LaLdDX); late-initiated, medium cumulative dose of systemic dexamethasone (LaMdDX); late-initiated, high cumulative dose of systemic dexamethasone (LaHdDX); early-initiated systemic hydrocortisone (EHC); late-initiated systemic hydrocortisone (LHC); early-initiated inhaled budesonide (EIBUD); early-initiated inhaled beclomethasone (EIBEC); early-initiated inhaled fluticasone (EIFLUT); late-initiated inhaled budesonide (LIBUD); late-initiated inhaled beclomethasone (LIBEC); and intratracheal budesonide (ITBUD). DATA SOURCES: PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, World Health Organization's International Clinical Trials Registry Platform (ICTRP), and CINAHL were searched from inception through August 25, 2020. STUDY SELECTION: In this systematic review and network meta-analysis, the randomized clinical trials selected included preterm neonates with a gestational age of 32 weeks or younger and for whom a corticosteroid regimen was initiated within 4 weeks of postnatal age. Peer-reviewed articles and abstracts in all languages were included. DATA EXTRACTION AND SYNTHESIS: Two independent authors extracted data in duplicate. Network meta-analysis used a bayesian model. MAIN OUTCOMES AND MEASURES: Primary combined outcome was BPD, defined as oxygen requirement at 36 weeks' postmenstrual age (PMA), or mortality at 36 weeks' PMA. The secondary outcomes included 15 safety outcomes. RESULTS: A total of 62 studies involving 5559 neonates (mean [SD] gestational age, 26 [1] weeks) were included. Several regimens were associated with a decreased risk of BPD or mortality, including EHC (risk ratio [RR], 0.82; 95% credible interval [CrI], 0.68-0.97); EIFLUT (RR, 0.75; 95% CrI, 0.55-0.98); LaHdDX (RR, 0.70; 95% CrI, 0.54-0.87); MoHdDX (RR, 0.64; 95% CrI, 0.48-0.82); ITBUD (RR, 0.73; 95% CrI, 0.57-0.91); and MoMdDX (RR, 0.61; 95% CrI, 0.45-0.79). Surface under the cumulative ranking curve (SUCRA) value ranking showed that MoMdDX (SUCRA, 0.91), MoHdDX (SUCRA, 0.86), and LaHdDX (SUCRA, 0.76) were the 3 most beneficial interventions. ITBUD (RR, 4.36; 95% CrI, 1.04-12.90); LaHdDX (RR, 11.91; 95% CrI, 1.64-44.49); LaLdDX (RR, 6.33; 95% CrI, 1.62-18.56); MoHdDX (RR, 4.96; 95% CrI, 1.14-14.75); and MoMdDX (RR, 3.16; 95% CrI, 1.35-6.82) were associated with more successful extubation from invasive mechanical ventilation. EHC was associated with a higher risk of gastrointestinal perforation (RR, 2.77; 95% CrI, 1.09-9.32). MoMdDX showed a higher risk of hypertension (RR, 3.96; 95% CrI, 1.10-30.91). MoHdDX had a higher risk of hypertrophic cardiomyopathy (RR, 5.94; 95% CrI, 1.95-18.11). CONCLUSIONS AND RELEVANCE: This study suggested that MoMdDX may be the most appropriate postnatal corticosteroid regimen for preventing BPD or mortality at a PMA of 36 weeks, albeit with a risk of hypertension. The quality of evidence was low.
引用
- Ramaswamy VV, Bandyopadhyay T, Nanda D, et al. Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis. JAMA Pediatr. 2021. PMID: 33720274. doi:10.1001/jamapediatrics.2020.6826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。